Pathology: Autistic Disorder

  • September 2010
  • -
  • Global Data



GlobalData, the market analysis specialist, has released its new report, “Autistic Disorder – Pipeline Assessment and Industry Projections to 2017”. The report is an essential source of information and analysis on the global Autistic Disorder industry . The report identifies the major industry developments shaping and driving the global Autistic Disorder industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Autistic Disorder segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.

GlobalData has estimated the global autistic disorder therapeutics industry to be valued at USD 331m in 2009. It is expected to grow to USD 765m with a compound annual growth rate (CAGR) of 11.05% by 2017. This growth is primarily attributed to the high increase in prevalence and also the rapid increase in public awareness about the disease. The existing industry is weak due to a lack of diagnostic techniques, and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. Autistic disorder therapeutics industry primarily consists of two products, Risperidone and Abilify, and other therapeutic classes such as anti-depressants and anti-psychotics.

Scope of the Research

- The report provides data on the key drivers and challenges of the Autistic Disorder industry . Its Scope of the Research includes:
- Annualized global Autistic Disorder industry revenues data from 2001 to 2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as noradrenaline reuptake inhibitors, adrenergic uptake inhibitors, enzyme replacement therapy, dopamine agents, chelating agents and Gamma-amino butyric acid type B (GABA-B) receptor agonist
- Analysis of the current and future competition in the global Autistic Disorder industry . Key industry players covered are Bristol-Myers Sqibb, Cellceutix Corporation, Seaside Therapeutics, Curemark LLC, Neuropharm Group and EilyLily.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Autistic Disorder therapeutics industry .

Why Should You Get This Report?

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Autistic Disorder industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Autistic Disorder industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Autistic Disorder industry landscape? – Identify, understand and decide.

Table Of Contents

1 Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 4

II Autistic Disorder March ket: Introduction 5
II. 1 GlobalData Pipeline Report Guidance 5

III Autistic Disorder March ket: March ket Characterization 6
III. 1 Autistic Disorder Therapeutics March ket Size 6
III. 2 Autistic Disorder March ket Forecasted data and CAGR 7
III. 3 Drivers and Barriers for the Autistic Disorder Therapeutics March ket 9
III. 3.1 Drivers for the Autistic Disorder Therapeutics March ket 9
III. 3.2 Barriers for the Autistic Disorder Therapeutics March ket 9
III. 4 Opportunity and Unmet Need 10
III. 5 Key Takeaway 11

IV Autistic Disorder March ket: Competitive Assessment 12
IV. 1 Overview 12
IV. 2 Strategic Competitor Assessment 12
IV. 3 Product Profile for the Major March keted Products in the Autistic Disorder Therapeutics March ket 13
IV. 3.1 Risperidone 13
IV. 3.2 Abilify 13
IV. 4 Key Takeaway 15

V Autistic Disorder March ket: Pipeline Assessment 16
V. 1 Overview 16
V. 2 Strategic Pipeline Assessment 16
V. 2.1 Technology Trends Analytic Framework 16
V. 3 Autistic Disorder Therapeutics - Promising Drugs under Clinical Development 17
V. 4 Molecule Profile for Promising Drugs under Clinical Development 18
V. 4.1 Galantamine 18
V. 4.2 Atomoxetine 18
V. 4.3 CM-AT 19
V. 5 Autistic Disorder March ket - Clinical Pipeline by Mechanism of Action 20
V. 6 Autistic Disorder Pipeline - Pipeline by Clinical Phases of Development 21
V. 6.1 Autism Disorder Therapeutics - Phase III Clinical Pipeline 21
V. 6.2 Autistic Disorder Therapeutics - Phase II Clinical Pipeline 22
V. 6.3 Autistic Disorder Therapeutics - Phase I Clinical Pipeline 22
V. 6.4 Autistic Disorder Therapeutics - Discovery Pipeline 23
V. 7 Key Takeaway 23

VI Autistic Disorder March ket: Implications for Future March ket Competition 24

VII Autistic Disorder March ket: Future Players in the Autistic Disorder March ket 25
VII. 1 Introduction 25
VII. 2 Bristol-Myers Squibb 26
VII. 2.1 Company Profile 26
VII. 2.2 Financial Performance 26
VII. 2.3 Business Overview 26
VII. 3 Cellceutix Corporation 27
VII. 3.1 Company Profile 27
VII. 3.2 Financial Performance 27
VII. 4 Seaside Therapeutics 28
VII. 4.1 Company Profile 28
VII. 5 Curemark LLC 28
VII. 5.1 Company Profile 28
VII. 6 Eli Lilly 29
VII. 6.1 Company Profile 29
VII. 6.2 Financial Performance 29
VII. 6.3 Business Overview 29
VII. 7 Neuropharm Group PLC 30
VII. 7.1 Overview 30
VII. 7.2 Major Products and Services 30
VII. 7.3 Autistic Disorder Disease Portfolio 31

VIII Autistic Disorder March ket: Appendix 32
VIII. 1 Definitions 32
VIII. 2 Acronyms 32
VIII. 3 Research Methodology 32
VIII. 3.1 Coverage 32
VIII. 3.2 Secondary Research 33
VIII. 3.3 Forecasted data ing 33
VIII. 3.4 Primary Research 36
VIII. 3.5 Expert Panel Validation 36
VIII. 4 Contact Us 36
VIII. 5 Disclaimer 36
VIII. 6 Sources 37

1.1 List of Data tables
Data table 1: Autistic Disorder March ket, Global, Sales s (USD Million), from 2001 to 2009 7
Data table 2: Autistic Disorder March ket, Global, Sales ($m) Forecasted data s, from 2009 to 2017 8
Data table 3: Major March keted Products Comparison in the Autistic Disorder therapeutics March ket, 2010 14
Data table 4: Autistic Disorder Therapeutics - Most Promising Drugs Under Clinical Development, 17
Data table 5: Autistic Disorder Therapeutics - Phase III Clinical Pipeline, 2010 21
Data table 6: Autistic Disorder Therapeutics - Phase II Clinical Pipeline, 2010 22
Data table 7: Autistic Disorder Therapeutics - Phase I Clinical Pipeline, 2010 22
Data table 8: Autistic Disorder Therapeutics - Discovery Pipeline, 2010 23
Data table 9: Cellceutix Corporation - Pipeline Products, 2010 27
Data table 10: Seaside Therapeutics - Autism Pipeline Products, 2010 28
Data table 11: Curemark LLC - Autism Pipeline Products, 2010 28
Data table 12: NeuroPharm Corporation - Autistic Disorder Pipeline Products, 2010 31

1.2 List of Charts
Chart 1: Autistic Disorder March ket, Global, Sales s (USD Million), from 2001 to 2009 7
Chart 2: Autistic Disorder March ket, Global, Sales (USD Million) Forecasted data s, from 2009 to 2017 8
Chart 3: Opportunity and Unmet Need in the Autistic Disorder Therapeutics March ket, 2010 10
Chart 4: Strategic Competitor Assessment of the Major March keted Products in Autistic Disorder Therapeutics, 2010 12
Chart 5: Technology Trends Analytic Framework of the Autistic Disorder Therapeutics Pipeline, 2010 16
Chart 6: Technology Trends Analytic Framework of the Autistic Disorder Therapeutics Pipeline - Description, 2010 17
Chart 7: Autistic Disorder March ket - Clinical Pipeline by Mechanism of Action, 2010 20
Chart 8: Autistic Disorder Therapeutics Pipeline by Phase of Clinical Development, 2010 21
Chart 9: Implications for Future March ket Competition in the Autistic Disorder March ket, 2010 24
Chart 10: Autistic Disorder Therapeutics March ket - Clinical Pipeline by Firms, 2010 25
Chart 11: GlobalData March ket Forecasted data ing Model 35

Companies mentioned
Bristol-Myers Squibb
Cellceutix Corporation
Seaside Therapeutics
Eli Lilly
Neuropharm Group PLC

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Depression – Pipeline Review, H1 2012

Pathology Industry: Depression – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.